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Elongase Reactions as Control Points in Long-Chain
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Abstract
Background: D6-Desaturase (Fads2) is widely regarded as rate-limiting in the conversion of dietary a-linolenic acid (18:3n-3;
ALA) to the long-chain omega-3 polyunsaturated fatty acid docosahexaenoic acid (22:6n-3; DHA). However, increasing
dietary ALA or the direct Fads2 product, stearidonic acid (18:4n-3; SDA), increases tissue levels of eicosapentaenoic acid
(20:5n-3; EPA) and docosapentaenoic acid (22:5n-3; DPA), but not DHA. These observations suggest that one or more
control points must exist beyond ALA metabolism by Fads2. One possible control point is a second reaction involving Fads2
itself, since this enzyme catalyses desaturation of 24:5n-3 to 24:6n-3, as well as ALA to SDA. However, metabolism of EPA
and DPA both require elongation reactions. This study examined the activities of two elongase enzymes as well as the
second reaction of Fads2 in order to concentrate on the metabolism of EPA to DHA.
Methodology/Principal Findings: The substrate selectivities, competitive substrate interactions and dose response curves
of the rat elongases, Elovl2 and Elovl5 were determined after expression of the enzymes in yeast. The competitive substrate
interactions for rat Fads2 were also examined. Rat Elovl2 was active with C20 and C22 polyunsaturated fatty acids and this
single enzyme catalysed the sequential elongation reactions of EPARDPAR24:5n-3. The second reaction DPAR24:5n-3
appeared to be saturated at substrate concentrations not saturating for the first reaction EPARDPA. ALA dose-dependently
inhibited Fads2 conversion of 24:5n-3 to 24:6n-3.
Conclusions: The competition between ALA and 24:5n-3 for Fads2 may explain the decrease in DHA levels observed after
certain intakes of dietary ALA have been exceeded. In addition, the apparent saturation of the second Elovl2 reaction,
DPAR24:5n-3, provides further explanations for the accumulation of DPA when ALA, SDA or EPA is provided in the diet.
This study suggests that Elovl2 will be critical in understanding if DHA synthesis can be increased by dietary means.
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Introduction
Metabolism of the vegetable-derived omega-3 (n-3) fatty acid, a-
linolenic acid (18:3n-3; ALA), to the long-chain n-3 polyunsatu-
rated fatty acids (PUFA), eicosapentaenoic acid (20:5n-3; EPA)
and docosahexaenoic acid (22:6n-3; DHA), requires progressive
desaturation and elongation. The location of regulatory steps in
the pathway has largely been inferred from the intermediate fatty
acids that accumulate in tissues following increased exposure to
ALA. With increasing abundance of ALA or stearidonic acid
(18:4n-3; SDA), which is the direct D6-desaturase (Fads2) product
of ALA desaturation, the next metabolite to accumulate is EPA
[1,2,3]. Although it is commonly reported that Fads2 is rate-
limiting for the metabolism of ALA to DHA, the accumulation of
EPA and not DHA suggests other control points need to be
considered [1,2,3]. As EPA increases, the next metabolite to
accumulate is the elongation product docosapentaenoic acid
(22:5n-3, DPA) [3]. The accumulation of EPA and DPA merit a
systematic examination of the elongase enzymes involved in their
metabolism. Human and rat elongase-5 (Elovl5) elongate C18 and
C20 PUFA [4,5] and human and mouse elongase-2 (Elovl2) are
active with C20 and C22 PUFA [6]. However, the putative
substrate preferences for these enzymes have been inferred from
separate studies, each using single concentrations of substrate.
Accordingly, these studies provide little insight into the reasons for
EPA and/or DPA accumulation when upstream precursor fatty
acids are abundant.
Beyond DPA formation, Fads2 may have an additional
influence on the pathway. In addition to metabolising ALA, it
also metabolises 24:5n-3, a progenitor of DHA. Since Fads2 is
used by two substrates in the pathway from ALA to DHA
synthesis, there is intrinsic potential for competitive substrate
inhibition. Substrate inhibition has been suggested as an
explanation for increasing EPA and DPA, but decreasing DHA
when dietary ALA is abundant [7,8]. However, direct competition
between ALA and 24:5n-3 with regard to Fads2 has not been
reported.
We report herein comparative studies of the rat elongases with
regard to expression, substrate selectivities, competitive substrate
interactions, and dose response curves. We also examined the
possible competitive substrate interactions for rat Fads2. The
enzyme activity studies used a yeast heterologous expression system.
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Results
Elongases
Sequence analysis of Elovl2 and Elovl5. Amplification of
the 840 bp Elovl2 ORF and subsequent alignment with the rat
Elovl2 sequence in GenBank (NM_001109118) revealed the two
sequences were identical. Amplification of the 900 bp Elovl5 ORF
and subsequent alignment with the rat Elovl5 sequence in
GenBank (NM_134382) revealed the two sequences had four
nucleotide differences. The Elovl5 sequence has been deposited in
GenBank as accession number HQ404314. The predicted Elovl2
and Elovl5 proteins of 279 and 299 amino acids, respectively,
included all of the characteristic features of a microsomal fatty acyl
elongase and had 56% identity. However, due to the nucleotide
changes in the Elovl5 sequence, the predicted Elovl5 protein
sequence included four residue differences from the rat Elovl5
sequence in GenBank (NP_599209). The Elovl2 and Elovl5
proteins are predicted to contain five and six transmembrane
regions, respectively (SOSUI software, http://bp.nuap.nagoya-u.
ac.jp/sosui/).
Comparison of Elovl2 and Elovl5 substrate
specificities. Recombinant S. cerevisiae cells expressing Elovl2
or Elovl5 were cultured in the presence of 100 mM of various C18-
22 PUFA to determine substrate specificities of the elongases.
Elovl5 demonstrated elongase activity with C18 and C20, but not
C22 PUFA (Fig. 1a). By contrast, Elovl2 demonstrated little activity
with C18 PUFA, but was active with C20 and C22 PUFA substrates
(Fig. 1b). The Elovl2 activity was 4.5- and 2.5-fold higher with the
n-3 substrates EPA and DPA, respectively, compared with their n-
6 homologs, arachidonic acid and 22:4n-6.
Competition between n-3 substrates for Elovl2 and
Elovl5. Since both SDA and its downstream product, EPA,
are substrates for Elovl5, there is the possibility of competition for
enzyme activity. However, over the concentration range
investigated there was no competitive inhibition of EPA
elongation by SDA, or SDA elongation by EPA (Fig. 2). The
elongation products of SDA and EPA were not detected in the
empty vector dose response experiments (Fig. 2). Elovl2 also has
two n-3 substrates, EPA and DPA. However, attempts to examine
possible competition between EPA and DPA were problematic
due to Elovl2 performing sequential reactions with EPA such that
DPA is both product and substrate. The sequential reactions with
Elovl2 were examined further.
Examination of product/substrate relationships for
Elovl2 and Elovl5. The initial results indicate that EPA at
100 mM can be used efficiently as a substrate by both Elovl2 and
Elovl5. For further comparisons, EPA dose response curves for the
two enzymes were made. For Elovl5 there was a proportional
increase in DPA synthesis with increasing EPA concentration
(Fig. 3a). For Elovl2 there was also a proportional increase in the
product of the first reaction, DPA, but not the product of the
second reaction, 24:5n-3 (Fig. 3b). This may suggest that the
second reaction of endogenously generated DPA conversion to
24:5n-3 is saturated at concentrations of EPA that are not
saturating for the first reaction, EPA conversion to DPA. When
DPA was used as an exogenous substrate, apparent saturation of
conversion to 24:5n-3 was also observed (Fig. 3c). The elongation
products of EPA and DPA were not detected in the empty vector
dose response experiments (Fig. 3).
Expression of Elovl2 and Elovl5 in rat liver and
heart. The dose responses indicate that both elongase
enzymes have similar affinities for EPA and therefore, both
could produce DPA. However, expression levels in vivo are quite
different with Elovl5 being present at much higher levels than
Elovl2 in liver and heart (Fig. 4). The expression of both Elovl5 and
Elovl2 was higher in liver compared to heart (Fig. 4).
D6-Desaturase (Fads2)
Sequence analysis of Fads2. Amplification of the 1335 bp
Fads2 ORF and subsequent alignment with the GenBank sequence
NM_031344 revealed one nucleotide difference. The Fads2
sequence was deposited in GenBank as accession number
HQ909027. The predicted Fads2 protein of 444 amino acids
contained one residue difference compared to NP_112634. The
residue change was not within the regions characteristic of fatty
Fgure 1. Comparison of the rat Elovl5 and Elovl2 substrate specificities. Recombinant S. cerevisiae expressing Elovl5 (A) or Elovl2 (B) were
grown in the presence of 100 mM of various C18, C20 and C22 PUFA substrates. Fatty acids were extracted from the recombinant S. cerevisiae and the
amount of each fatty acid was expressed as a percentage of the total amount of all fatty acids. The proportion of substrate fatty acid converted to
longer chain fatty acid product(s) was calculated as [product(s)/(product(s) + substrate)]6100. The product was 2 carbons longer than the substrate.
1 denotes that the conversion includes the 4 carbon elongation product. The results are the means 6 S.D. of triplicate incubations. Values with
different symbols are significantly different from each other. ND, not detected.
doi:10.1371/journal.pone.0029662.g001
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acyl desaturases; the conserved histidine boxes or cytochrome b5
domain containing the heme-binding motif.
Fads2 substrate specificities. Recombinant S. cerevisiae cells
expressing Fads2 were cultured in the presence of 100 mM of
various C18-24 PUFA substrates to determine the enzymes
substrate specificity. Fads2 demonstrated D6-desaturase activity
with the expected n-3 and n-6 substrates, ALA and LA, and with
24:5n-3 (Fig. 5). Fads2 did not exhibit D5-desaturase activity with
the substrates 20:4n-3 or 20:3n-6, or D8-desaturase activity with
the substrates 20:3n-3 and 20:2n-6 (data not shown).
Competition between n-3 C18 and C24 substrates for
Fads2. ALA and 24:5n-3 were both Fads2 substrates with
similar conversion efficiencies at a single concentration (Fig. 5).
Therefore, the potential for competitive inhibition was examined
at concentrations of ALA and 24:5n-3 that were in the linear
response range (Fig. 6). The concentration of 24:5n-3 that was
examined was much lower than the concentration of ALA.
However, 24:5n-3 is likely to be lower than ALA in vivo because
24:5n-3 is usually not detectable in ALA dietary studies. Increasing
concentrations of ALA over the range 0–400 mM dose-
dependently inhibited the conversion of 24:5n-3 to 24:6n-3 (Fig. 7).
Discussion
Our direct comparative study of the rat elongases showed that
the substrates for Elovl5 are C18 and C20 PUFA, while for Elovl2
they are C20 and C22 PUFA (Fig. 8). This is generally concordant
with specificities from separate studies of mouse Elovl2 [6], human
Elovl2 [6], human Elovl5 [4] and rat Elovl5 [5], although there
are some differences. The rELO1 (now Elovl5) examined by
Inagaki et al. [5] had four residue differences from the Elovl5
examined in this study and it had markedly greater preferences for
C18 over C20 substrates, both n-3 and n-6, which were not
observed in our study. Also, compared with the rat Elovl2 in our
study, the mouse Elovl2 appeared to convert EPA preferentially
through to 24:5n-3 with less accumulation of DPA [6]. However,
only a single concentration of EPA was used in the mouse study.
We have shown that the proportion of EPA converted to 24:5n-3
by Elovl2 compared with that accumulating as DPA, diminishes
with increasing EPA concentration. A possible explanation is that
the second reaction, DPA to 24:5n-3, becomes saturated.
We also examined competitive substrate interactions. Elovl2
and Elovl5 each have at least two n-3 substrates, raising the
Figure 2. Competition between n-3 PUFA substrates for elongation by Elovl5. Recombinant S. cerevisiae expressing Elovl5 were grown in
the presence of 100 mM of SDA and 0–300 mM EPA (A) or 100 mM of EPA and 0–300 mM SDA (B). Recombinant S. cerevisiae containing the empty
pYES2 vector were grown in the presence of 0–300 mM EPA or SDA. Fatty acids were extracted from the recombinant S. cerevisiae and the amount of
each fatty acid was quantified in mg g21 of S. cerevisiae or expressed as a percentage of the total amount of all fatty acids. The proportion of substrate
fatty acid converted to longer chain fatty acid product(s) was calculated as [product(s)/(product(s) + substrate)]6100. The conversion of SDA includes
the 4 carbon elongation product 22:4n-3. The results are the means 6 S.D. of triplicate incubations. Values with different symbols are significantly
different from each other.
doi:10.1371/journal.pone.0029662.g002
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potential for competitive substrate inhibition. Although SDA and
EPA are both Elovl5 substrates, there was no evidence to suggest
n-3 PUFA competition between substrates at the concentrations
used in this study. Luthria and Sprecher [9] reported that neither
EPA nor DPA inhibited SDA elongation in rat liver microsomes,
although at the time they were unaware of which elongase enzyme
Figure 3. Examination of product/substrate relationships for elongation by Elovl5 and Elovl2. Recombinant S. cerevisiae expressing
empty pYES2 vector or Elovl5 were grown in the presence of EPA (A) or recombinant S. cerevisiae expressing empty pYES2 vector or Elovl2 were
grown in the presence of EPA (B) or DPA (C). Fatty acids were extracted from the recombinant S. cerevisiae and the amount of each fatty acid was
quantified in mg g21 of S. cerevisiae. The results are the means 6 S.D. of triplicate incubations. Values with different symbols are significantly different
from each other.
doi:10.1371/journal.pone.0029662.g003
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was responsible. It is clear now that DPA does not inhibit SDA
elongation because they are substrates for different enzymes,
Elovl2 and Elovl5, respectively. However, we confirm that EPA
does not appear to inhibit SDA elongation by Elovl5.
The sequential reactions of EPARDPAR24:5n-3 performed by
Elovl2 presented difficulties for examining possible competition
between EPA and DPA (Fig. 8). Attempts were made to examine
EPA/DPA competition, but results were uninterpretable due to
DPA being both product and substrate with the same enzyme. Use
of labelled EPA was considered, but was discounted due to similar
concerns with interpretation of the results. However, the dose
response of EPA with Elovl2 provided insights into the one
enzyme dual reaction processes. With increasing EPA concentra-
tions up to 400 mM, DPA increased proportionately whereas the
subsequent product, 24:5n-3, reached a plateau at 200 mM EPA.
This could reflect competition from EPA for the second reaction,
DPAR24:5n-3. However, the simpler explanation is that the
Elovl2 second reaction, DPAR24:5n-3, may be saturated at a
lower substrate concentration than the first reaction, EPARDPA.
This explanation is supported by the demonstration of apparent
saturation of the reaction DPAR24:5n-3 using DPA as the
exogenous substrate. Possible saturation of the Elovl2 second
reaction in the absence of saturation of the first reaction provides
an additional explanation for the increase of DPA but not DHA
after certain concentrations/intakes of ALA have been exceeded.
These conclusions are contingent in part on the expressed
elongases being rate limiting for the process of elongation which
requires the Elovl enzyme and three additional enzymes. The
Elovl enzyme catalyses the initial condensation reaction while the
enzymes required for the subsequent reduction-dehydration-
reduction steps necessary for complete elongation are supplied
by the yeast [10]. However, it has been shown that the
condensation reaction is the rate-limiting step in elongation, even
in a yeast heterologous expression system [10].
The rat Fads2 was active with the conventional D6-desaturase
C18 and C24 PUFA substrates, but does not have D5- or D8-
desaturase activity. This was unlike the baboon Fads2 which had
D6- and D8-desaturase activity [11]. However, our findings with
Fads2 are in agreement with previous studies that confirmed lack
of D5-desaturase activity with the rat enzyme expressed in yeast or
the mouse enzyme expressed in primary cultures of rat hepatocytes
and in CHO cells, although these studies did not report activity
values and did not examine C24 PUFA substrates [12,13]. A later
study indirectly examined the rat D6-desaturase activity towards
the C24 substrates by expressing the enzyme in COS-7 cells [14].
The transfected cells were supplemented with DPA or 22:4n-6,
relying on the endogenous cellular elongases to produce the D6-
desaturase substrates 24:5n-3 and 24:4n-6 [14]. This study
suggested that the rat D6-desaturase was more active towards
ALA than 24:5n-3 although it is difficult to compare D6-desaturase
activity when ALA was supplied exogenously but 24:5n-3 was
formed endogenously.
Fads2 has been accepted as a control point in the production of
DHA from ALA. Fads2 is an essential enzyme because DHA was
not present or substantially reduced in Fads2 knockout mice
[15,16,17]. The contribution of Fads2 in controlling the synthesis
of DHA is two-fold. It is rate-limiting for conversion of ALA to
EPA [1,2,3] and it also converts 24:5n-3, the product of Elovl2
activity, to 24:6n-3. Thus, there is the potential for competitive C18
and C24 n-3 substrate interactions and this could limit one or both
reactions. Although it has been suggested there is competition
between the C18 and C24 n-3 substrates for Fads2, it had not been
investigated directly [7,8]. The Fads2 dose response with ALA and
24:5n-3 was used to select a series of 24:5n-3/ALA ratios to
examine competition. In ALA dietary studies with rats or humans
where ALA is readily detectable in membrane phospholipids,
24:5n-3 is not detectable or barely detectable. Therefore, we
examined ratios with ALA as the predominant fatty acid as we
considered this would reflect in vivo ratios more closely compared
with ratios in the other direction. Our study demonstrated that
increasing concentrations of ALA can inhibit the conversion of
24:5n-3. This directly supports suggestions that the competition
between ALA and 24:5n-3 may explain the decreasing DHA levels
after certain intakes of ALA are exceeded [7,8].
The present study indicates that Elovl2 is another potential
control point, additional to that of Fads2. The scheme in Fig. 8
places the elongases according to their substrate selectivities.
Although both Elovl2 and Elovl5 could catalyse EPA to DPA
Figure 4. Comparison of the absolute number of Elovl2 and
Elovl5 mRNA template copies / ng of total RNA in rat liver and
heart. Elovl2 was detected in heart at ,10 copies / ng of total RNA. All
measurements were performed in duplicate and the results are the
mean 6 S.E.M. (n = 3).
doi:10.1371/journal.pone.0029662.g004
Figure 5. The rat Fads2 substrate specificity. Recombinant S.
cerevisiae expressing Fads2 were grown in the presence of 100 mM of
various PUFA substrates. Fatty acids were extracted from the
recombinant S. cerevisiae and the amount of each fatty acid was
expressed as a percentage of the total amount of all fatty acids. The
proportion of substrate fatty acid converted to desaturation product
was calculated as [product/(product + substrate)]6100. The product
contained one more double bond than the substrate. The results are
the means 6 S.D. of triplicate incubations. Values with different
symbols are significantly different from each other.
doi:10.1371/journal.pone.0029662.g005
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conversion, Elovl5 may be more important since our data show it
is expressed at much higher levels than Elovl2 in rat liver and
heart. However, neither EPA nor DPA elongation were
diminished in the liver of Elovl5-/- mice, indicating that Elovl2
was responsible for EPA elongation in these knockout mice [18].
Nevertheless, Elovl2 was upregulated substantially in the Elovl5-/-
mice compared with the wild type controls [18]. The serum of
Elovl2-/- mice had elevated EPA and DPA levels [19]. However,
Elovl5 may have been upregulated in the Elovl2-/- mice resulting in
the accumulation of EPA and DPA, analogous to the upregulation
of Elovl2 in Elovl5-/- mice, although this was not investigated [19].
Therefore, it remains uncertain if one or both elongases normally
contribute to EPA elongation.
The scheme in Fig. 8 highlights the essentiality of Elovl2 activity
for DHA formation. The finding that 24:5n-3 formation is possibly
saturated at substrate concentrations not saturating for DPA
formation, provides explanations for previous dietary findings. For
example, tracer studies in healthy volunteers showed that
increased EPA intake as a fish-based diet, increased the mass of
EPA to DPA conversion, but decreased the mass of DPA to 24:5n-
3 conversion [20]. The scheme proposed in Fig. 8 suggests these
reported results could be due to increased EPA saturating the
second Elovl2 reaction and competing with DPA for Elovl2
activity. The possible saturation of the second Elovl2 reaction
provides an explanation for the limitations of both ALA and EPA
as progenitors of DHA formation and provides an explanation for
the accumulation of DPA when ALA or SDA or EPA is provided
in the diet [1,2,3].
SDA enriched soybeans were granted Generally Recognised As
Safe (GRAS) status by the US FDA in 2009 (http://www.
soymega.com/en/Why-Soymega/). Bypassing the first Fads2
reaction has the potential to improve EPA and DPA tissue levels
compared with standard soybean products. However, the present
study suggests that Elovl2, both its presence and its activity, will be
critical in understanding if DHA synthesis can be increased by
dietary means.
Given the essentiality of Elovl2 for DHA synthesis, a functional
Elovl2 may control the habitat and diet of a range of species such
Figure 6. Examination of product/substrate relationships for desaturation by Fads2. Recombinant S. cerevisiae expressing empty pYES2
vector or Fads2 were grown in the presence of ALA (A) or 24:5n-3 (B). Fatty acids were extracted from the recombinant S. cerevisiae and the amount
of each fatty acid was quantified in mg g21 of S. cerevisiae. The results are the means6 S.D. of triplicate incubations. Values with different symbols are
significantly different from each other.
doi:10.1371/journal.pone.0029662.g006
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as fish, chickens, rats and humans. Freshwater fish and salmonids
which consume herbivorous or omnivorous diets are generally
considered to be capable of synthesizing DHA from ALA.
Interestingly, zebrafish and Atlantic salmon are the only non-
mammalian vertebrates with a functionally characterised Elovl2
[21,22]. Searches of the ENSEMBL genomes suggest that the
carnivorous fish species Tetraodon nigroviridis and Gasterosteus aculeatus
and even omnivorous fish species Takifugu rubripes and Oryzais latipes
do not contain Elovl2 homologs [22]. The lack of Elovl2 could
impose an absolute block on their ability to synthesize DHA from
ALA and accordingly Elovl2 may be a genetic marker for DHA
synthetic capacity of a species.
Materials and Methods
Materials
All reagents were obtained from InvitrogenTM Australia Pty. Ltd.
(Mount Waverley, Vic, Aust.) unless otherwise stated. The PUFA
substrates and internal standard 17:0 were obtained from Nu-Chek
Prep, Inc. (MN, USA), Cayman Chemical Company (Sapphire
Bioscience, Australia) or Larodan Fine Chemicals (Malmo¨,
Sweden).
Cloning the Elovl2, Elovl5 and Fads2 cDNA
Total RNA was extracted from the livers of Dark Agouti rats
with the RNeasy kit (Qiagen, Australia). RT-PCR amplification of
the Elovl2, Elovl5 and Fads2 open reading frames (ORFs) was
performed using the primers in Table 1 and OneStep RT-PCR
Enzyme Mix (Qiagen). The primers were used to generate
restriction enzyme sites flanking the ORFs. The resulting cDNAs
and the expression vector pYES2 were restriction enzyme treated
and ligated using T4 DNA ligase (1.5 Weiss units) (Promega, WI,
USA). Transformation of the resulting constructs, pYES2-Elovl2,
pYES2-Elovl5 and pYES2-Fads2 into MAX EfficiencyH DH5aTM
Competent E. coli cells was performed using heat-shock. Putative
transformants were selected using 100 mg mL-1 ampicillin and
PCR screening. Recombinant plasmids were purified and the
presence of the gene insert in the correct orientation was
confirmed via sequencing at the Institute of Medical and
Veterinary Science (Adelaide, Australia).
Heterologous expression of the Elovl2, Elovl5 and Fads2
ORFs in Saccharomyces cerevisiae
The pYES2-Elovl2, pYES2-Elovl5 and pYES2-Fads2 constructs
were used to transform Saccharomyces cerevisiae strain INVSc1 for the
production of recombinant protein, using the S. c. EasyCompTM
Transformation Kit. Successfully transformed yeast cells were selected
on uracil dropout medium. Recombinant yeast cells were maintained
in synthetic minimal defined medium for yeast without uracil
containing 2% glucose. Upon fatty acid supplementation, glucose
was replaced with 2% galactose for induction of gene expression.
Figure 7. Competition between n-3 PUFA substrates for
desaturation by Fads2. Recombinant S. cerevisiae expressing Fads2
were grown in the presence of 25 mM of 24:5n-3 and 0–400 mM ALA.
Fatty acids were extracted from the recombinant S. cerevisiae and the
amount of each fatty acid was expressed as a percentage of the total
amount of all fatty acids. The proportion of substrate fatty acid
converted to desaturation product was calculated as [product/(product
+ substrate)]6100. The results are the means 6 S.D. of triplicate
incubations. Values with different symbols are significantly different
from each other.
doi:10.1371/journal.pone.0029662.g007
Figure 8. N-3 long-chain polyunsaturated fatty acid synthesis showing two-stages of D6-desaturase involvement and the individual
elongase involvement. ? denotes that Elovl5 or Elovl2 can catalyse this reaction.
doi:10.1371/journal.pone.0029662.g008
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Recombinant yeast expressing Elovl2 or Elovl5 were supple-
mented with one or more of the following PUFA substrates: 18:4n-
3 (SDA), 18:3n-6 (c-linolenic acid; GLA), 20:5n-3 (EPA), 20:4n-6
(arachidonic acid; AA), 22:5n-3 (DPA) or 22:4n-6.
Recombinant yeast expressing Fads2 were supplemented with
one or more of the following putative D6-desaturase substrates:
18:3n-3 (ALA), 18:2n-6 (linoleic acid; LA) or 24:5n-3; D5-
desaturase substrates: 20:4n-3 or 20:3n-6; D8-desaturase sub-
strates: 20:3n-3 or 20:2n-6.
PUFA substrates were prepared in ethanol. The volume of
ethanol in each incubation was kept constant. Cells were harvested
for analysis after 24 h of fatty acid supplementation at 30uC. The
cells were pelleted by centrifugation at 1500 g for 5 min and the
cell pellets were washed with 0.85% saline. The wet weights of the
cell pellets were recorded. Data are expressed as the means 6 SD
of triplicate incubations for each treatment.
Elovl2 and Elovl5 expression levels
Dark Agouti rats consumed a fat free AIN-93G rodent diet
(Glen Forrest Stockfeeders, Glen Forrest, Western Australia)
blended with flaxseed oil to obtain 1%en ALA and 2.1%en LA,
to a level of 5% (w/w) fat. The experiment was approved by the
Animal Ethics Committee of the Institute of Medical and
Veterinary Science (125/06) and was performed in accordance
with the National Health and Medical Research Council
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes. Total RNA was extracted from the liver or
heart of the rats with the RNeasy kit (Qiagen). The quantity and
quality of RNA was determined by measuring the absorbance at
260 and 280 nm (NanoDrop Technologies Inc., DE, USA) and
agarose gel electrophoresis. Total RNA (0.5 mg) was reverse
transcribed into cDNA using the QuantiTectH Reverse Tran-
scription kit (Qiagen). Quantitative reverse transcription-polymer-
ase chain reaction (qRT-PCR) was performed using a Rotor-Gene
3000 (Corbett Research) with the QuantiFastTM SYBRH Green
PCR kit (Qiagen). Each reaction contained 10 ng of cDNA, 5 ml
QuantiFastTM SYBRH Green PCR master mix and 1 ml of
QuantiTectH Primer Assay (Qiagen), in a total volume of 10 ml.
The QuantiTectH Primer Assays used were Elovl2 (Rn_E-
lovl2_2_SG, QT01683899) and Elovl5 (Rn_Elovl5_1_SG,
QT00178059). Elovl2 or Elovl5 PCR products were used to make
10-fold serial dilutions from 106 copies down to 10 copies. The
PCR product standard curve equations were used to calculate the
absolute copy number of Elovl2 and Elovl5 in rat liver and heart.
The cycling conditions were as follows: PCR initial activation step
at 95uC for 5 min, 2 step cycling with 35 cycles of denaturation at
95uC for 10 s and annealing/extension at 60uC for 30 s. Each
amplification was performed in duplicate.
Fatty acid analysis
Total lipid was extracted from yeast cells and analysed by gas
chromatography as previously described [23]. The identities of
20:4n-3 and 22:4n-3 were previously confirmed by gas chroma-
tography–mass spectrometry [23]. The internal free fatty acid
standard 17:0 was used to quantify the amount of each
endogenous fatty acid. The proportion of substrate fatty acid
converted to fatty acid product(s) was calculated as [product(s)/
(product(s) + substrate)]6100.
Statistical analysis
One-way ANOVA with Tukey’s post-hoc test was performed
using Graphpad Prism version 5.03 for Windows (Graphpad
Software, San Diego, CA, USA). Statistical significance was set at
P,0.05.
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